Skip to content

Asper Biogene OÜ

Registry code (registrikood) 14265334Private limited company (Osaühing)VAT EE101984009Activity (EMTAK 72101): Teadus- ja arendustegevus loodus- ja tehnikateaduste vallasActive

Tartu linn, Tartu County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€589k
▼ 9.3% vs 2024
Profit before tax (2025)
-€168k
Employees, FTE (2025)
9
State taxes paid, last 4 quarters
€124k

Revenue, profit and employees, 2019–2025

€682k2019€787k2020€652k2021€782k2022€825k2023€650k2024€589k2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€681,879€12,805€14,050€100,27314
2020€786,521€56,924€40,641€140,91413
2021€651,969€43,345€35,465€176,37911
2022€782,438€188,080€155,811€332,1909
2023€825,111€20,191€14,628€346,8189
2024€649,888-€62,756-€66,368€280,4509
2025€589,232-€162,968-€167,803€112,6479

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€83,231€323,817€133,344€90,200€100,273
2020€50,155€353,107€169,198€42,995€140,914
2021€39,536€422,487€203,113€42,995€176,379
2022€41,565€594,688€241,220€21,278€332,190
2023€33,748€491,614€123,518€21,278€346,818
2024€64,604€391,956€90,228€21,278€280,450
2025€33,423€227,003€95,078€19,278€112,647

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€35,713€30,893€67,08814
2022 Q2€38,984€26,883€55,02413
2022 Q3€26,415€24,262€49,68813
2022 Q4€26,755€25,455€51,71413
2023 Q1€49,657€26,425€110,96112
2023 Q2€37,958€25,547€99,90311
2023 Q3€29,034€24,126€58,62511
2023 Q4€38,350€24,729€113,16911
2024 Q1€26,583€29,172€80,26713
2024 Q2€36,851€30,520€85,18213
2024 Q3€33,350€24,121€67,21213
2024 Q4€27,162€20,580€72,54113
2025 Q1€26,123€23,024€50,10013
2025 Q2€33,329€24,406€72,39013
2025 Q3€31,812€24,010€62,09013
2025 Q4€32,395€25,565€53,64312
2026 Q1€40,977€28,024€61,73011
2026 Q2€27,370€19,577€62,57011
2026 Q3€23,311€20,288€43,01711

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), Asper Biogene OÜ reported revenue of €589,232.

The company recorded a net loss of €167,803 in the 2025 financial year.

Revenue decreased by 9.3% from €649,888 in 2024 to €589,232 in 2025.

Revenue grew at a compound annual rate of -2.4% between 2019 and 2025.

Equity accounted for 49.6% of total assets of €227,003 at the end of the 2025 reporting period.

With 9 full-time-equivalent employees in 2025, revenue per employee was €65,470.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, Asper Biogene OÜ reported €220,960 in turnover.

EMTA recorded 11 employees for the quarter ending Q3 2026, compared with 9 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.